PA5-27134

antibody from Invitrogen Antibodies

Targeting: CTTN EMS1

Provider product page for PA5-27134

Western blot

Immunocytochemistry

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Immunocytochemistry [1]
Other assay [2]

Submit

Product number: PA5-27134 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cortactin Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Recommended positive controls: HeLa, HepG2, NIH-3T3, JC, PC-12, mouse brain, rat brain. Predicted reactivity: Rhesus Monkey (100%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

CTTN protein structure - PA5-27134 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Mitochondrial dysfunction is observed in CD8 + but not CD4 + EMRA T cell subsets. (a) Representative flow cytometry plots and cumulative graphs of TMRE staining from middle-aged donors showing membrane potential in CD45RA/CD27 T cell subsets directly ex vivo defined showing the percentage of cortactin-positive (a) CD4 + and (b) CD8 + T cells analysed directly ex vivo. Data expressed as mean +- SEM of six donors. (b) Mitochondrial ROS measured using MitoSOX by flow cytometry in CD4 + and CD8 + EMRA T cells from middle-aged donors. Data expressed as mean +- SEM of six donors. (c) Mitochondrial ROS production expressed as a ratio of mitochondrial mass. Calculated from data shown in Figures 1 b and 2 . (d) gammaH2AX expression as determined by flow cytometry in CD45RA/CD27-defined T cell subsets directly ex vivo from middle-aged donors; the graph shows the mean +- SEM for five donors. (e) Oxygen consumption rates (OCR) of the EMRA CD4 + and CD8 + T cell subsets from middle-aged donors were measured following a 15-min stimulation with 0.5 ug/ml anti-CD3 and 5 ng/ml IL-2; the cells were then subjected to a metabolic stress test using the indicated mitochondrial inhibitors. Data are representative of four independent experiments. (f) The basal OCR, extracellular acidification rate (ECAR) and spare respiratory capacity were measured following a 15-min stimulation with 0.5 ug/ml anti-CD3 and 5 ng/ml IL-2. Graphs show the mean +- SEM for four donors. (g) ATP concentration in E

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Impaired function observed in CD8 + EMRA T cells. (a) Example and graph showing the expression of p-p53 in CD4 + and CD8 + CD45RA/CD27-defined EMRA T cells directly ex vivo from middle-aged donors. Graphs show the mean +- SEM for four donors. (b) Proliferation was defined in senescent T cell subsets using Ki67 directly ex vivo from middle-aged donors . Data show the mean +- SEM for 12 donors. (c) The migration of CD4 + and CD8 + EMRA T cells from middle-aged donors through HUVECs and their supporting transwell filters. HUVECs were stimulated with 20% decomplemented (heated at 56degC for 20 min) autologous donor sera for 24 hr. PBMCs were allowed to adhere and migrate for 4 hr towards either media, CXCL10/12 or autologous serum. The number of T cells was counted and expressed as a percentage of the total migrated CD4 + or CD8 + T cells. Data are expressed as the mean +- SEM of six donors. (d) Representative flow cytometry plots and cumulative graphs showing the percentage of cortactin-positive senescent T cell subsets analysed directly ex vivo from middle-aged donors. Data expressed as mean +- SEM of seven donors. p -values were calculated using a t test. * p < .05, ** p < .01, *** p < .005, and **** p < .001